Asymchem Laboratories (Tianjin) Co., Ltd.
凱萊英醫藥集團（天津）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6821)

2022 FIRST QUARTERLY REPORT

This announcement is made by Asymchem Laboratories (Tianjin) Co., Ltd. (凱萊英醫藥集團（天津）股份有限公司) (the "**Company**" and together with its subsidiaries, the "**Group**") pursuant to Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The following is the first quarterly report for 2022 of the Company. The financial data contained in this quarterly report is prepared in accordance with the PRC Accounting Standards for Business Enterprises. The first quarterly report for 2022 of the Company has not been audited.

The first quarterly report for 2022 of the Company is written in both Chinese and English. In the case of any discrepancies, the Chinese version of the report shall prevail.

By order of the Board
Asymchem Laboratories (Tianjin) Co., Ltd.
Dr. Hao Hong
Chairman of the Board, Executive Director and Chief Executive Officer

Tianjin, April 20, 2022

As of the date of this announcement, the Board of Directors of the Company comprises Dr. Hao Hong as the Chairman of the Board of Directors and executive Director, Ms. Yang Rui, Mr. Zhang Da and Mr. Hong Liang as executive Directors, Dr. Ye Song and Ms. Zhang Ting as non-executive Directors, and Ms. Zhang Kun, Mr. Wang Qingsong and Mr. Lee, Kar Chung Felix as independent non-executive Directors.

Asymchem Laboratories (Tianjin) Co., Ltd.

2022 FIRST QUARTERLY REPORT

The Company and all the directors of the Company (the "**Directors**") hereby confirm the truthfulness, accuracy and completeness of the contents of this announcement and does not contain any false representation, misleading statement or material omission.

IMPORTANT NOTICE:

1. The board of directors of the Company (the "**Board**"), the supervisory committee of the Company and the Directors, supervisors and senior management of the Company confirm that this report does not contain any false information, misleading statements or material omissions, and individually and collectively accept responsibility for the truthfulness, accuracy and completeness of its contents.

2. The person in charge of the Company, the chief financial officer and the person in charge of accounting department (accounting head) of the Company, hereby confirm the truthfulness, accuracy and completeness of the financial report contained in this quarterly report.

3. Whether the first quarterly report is audited or not
   ☐ Yes √ No

I. MAJOR ACCOUNTING DATA

(I) Major Accounting Data and Financial Indicators

Does the Company require a retroactive adjustment or restatement on the previous period of financial data

☐ Yes √ No

	The Reporting Period	Same period last year	Increase/Decrease Comparing with the Same Period Last Year
Operating Revenue *(RMB)*	2,061,708,856.14	777,189,276.45	165.28%
Net profit attributable to shareholders of the listed company *(RMB)*	499,398,084.81	154,330,479.55	223.59%
Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss *(RMB)*	486,390,519.38	129,442,396.10	275.76%
Net cash flow from operating activities *(RMB)*	204,607,061.83	100,659,080.60	103.27%
Basic earnings per share *(RMB)*	1.91	0.64	198.44%
Diluted earnings per share *(RMB)*	1.90	0.64	196.88%
Weighted average return on net assets	3.88%	2.14%	1.74%

	At the end of the current Reporting Period	At the end of last year	Increase/decrease as at the end of the Reporting Period compared to the end of the last year
Total assets *(RMB)*	16,389,663,097.90	15,156,297,270.34	8.14%
Owners' equity attributable to shareholders of the listed company *(RMB)*	13,514,177,861.13	12,610,011,324.42	7.17%

(II) Non-recurring Profit or Loss Items and Amount

√ Applicable □ Not Applicable

Unit：RMB

Items	Amount
Government subsidies included in profit or loss for the current period (excluding the sustained quota or amount subsidized according to the state policies that are closely relevant to the Company's normal operations)	8,038,406.63
Apart from effective hedging instruments relating to the normal operations of the Company, profit or loss from change in fair value of held-for-trading financial assets and held-for-trading financial liabilities, and investment income from disposal of held-for-trading financial assets, held-for-trading financial liabilities and available-for-sale financial assets	10,284,400.30
Non-operating net gain or loss other than the above	-3,009,096.40
Less: Effect of extraordinary gains or losses on income tax	2,306,145.10
Total	13,007,565.43

Details of other profit or loss items that meet the definition of extraordinary gains or losses:

□ Applicable √ Not Applicable

The Company has no other gains or losses items that meet the definition of extraordinary gains or losses.

Explanation on the extraordinary gains or losses items listed in the Explanatory Announcement on Information Disclosure for Companies Offering Their Securities to the Public No. 1 – extraordinary gains or losses as recurring profit or loss items

□ Applicable √ Not Applicable

The Company does not define the extraordinary gains or losses items listed in the Explanatory Announcement on Information Disclosure for Companies Offering Their Securities to the Public No. 1 – extraordinary gains or losses as recurring profit or loss items.

(III) Changes in the Major Accounting Data and Financial Indicators and the Reasons Therefor

√ Applicable □ Not Applicable

In the first quarter of 2022, the Company's total operating revenue was RMB2.062 billion, representing an increase of 165.28% year-on-year, and a year-on-year increase of 171.64% excluding the impact of exchange rate fluctuations. Net profit attributable to shareholders of the Company amounted to RMB499 million, representing an increase of 223.59% year-on-year, and adjusted net profit attributable to shareholders of the Company increased by 252.42% year-on-year. Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss amounted to RMB486 million, representing an increase of 275.76% year-on-year.

Unit: RMB

Number	Balance sheet items	March 31, 2022	December 31, 2021	Percentage of change	Reason for change
1	Held-for-trading financial assets	887,856,000.00	401,198,333.33	121.30%	Mainly due to the purchase of short-term low-risk wealth management products with idle funds during the period.
2	Prepayments	435,948,192.20	221,947,942.22	96.42%	The significant increase in prepayments in the current period is mainly due to the increase in prepayments for equipment procurement.
3	Other receivable	30,895,268.45	23,116,427.35	33.65%	Mainly due to the increase in deposits/guarantees.
4	Contract asset	1,384,478.30	742,372.74	86.49%	Mainly due to the right to receive consideration for goods or services transferred to customers in the current period.
5	Other current asset	302,446,881.76	216,618,777.74	39.62%	Mainly due to the increase in export tax refund and value-added tax retained during the Reporting Period.
6	Accounts payable	858,848,577.04	551,866,159.80	55.63%	Mainly due to the increase in purchase of materials as orders increased during the Reporting Period.
7	Salaries payable	126,950,201.74	188,003,012.68	-32.47%	Mainly due to the year-end bonus to be distributed was included at the end of the previous period.
8	Other current liabilities	7,357,083.06	5,401,028.91	36.22%	Mainly due to the increase in value-added tax corresponding to the increase in advances from customers in the current period.
9	Deferred income tax liabilities	157,589,389.65	116,553,640.51	35.21%	Mainly due to the increase in deferred tax liabilities resulting from accelerated depreciation of fixed assets during the period.

Number	Balance sheet items	January to March, 2022	January to March, 2021	Percentage of change	Reason for change
1	Total operating revenue	2,061,708,856.14	777,189,276.45	165.28%	During the Reporting Period, the Company's revenue grew strongly, and the "two-wheel drive" strategy was effectively promoted. The small molecule business increased by 165.9% year-on-year, the emerging business increased by 157.4% year-on-year, and the revenue growth rate of chemical macromolecule, biological macromolecule, drug product and clinical CRO exceeded 100%.
2	Cost of operation	1,128,892,034.57	444,047,380.18	154.23%	During the Reporting Period, the cost of sales increased at the same time, and the gross profit margin showed an upward trend as compared with the same period of last year, benefiting from the full utilization of the Company's production capacity.
3	Administrative expenses	162,978,091.37	98,610,120.31	65.28%	Mainly due to the increase in the number of employees of the Company and the increase in remuneration and share-based compensation expenses.
4	Research and development expenses	130,883,695.56	83,440,733.89	56.86%	Mainly due to the Company's continuous increase in R&D investment, increase in technology empowerment and development of technological innovation platform.
5	Finance costs	48,368,735.63	-7,161,138.84	775.43%	Mainly due to the exchange losses caused by exchange rate fluctuations.
6	Other gains	8,038,406.63	29,147,775.98	-72.42%	Mainly due to the decrease in government grants related to income received during the period.
7	Gain from investment	11,660,530.17	-87,873.58	13369.67%	Mainly due to the investment income from associates invested by the Company.
8	Income tax expenses	67,690,481.54	10,961,374.16	517.54%	Mainly due to the increase in income tax expenses as a result of the increase in profit for the period.
9	Net profit	499,398,084.81	154,329,304.12	223.59%	Mainly due to the increase in operating income and cost control during the period.

Number	Cash flow items	January to March, 2022	January to March, 2021	Percentage of change	Reason for change
1	Cash received from sales of goods and rendering of services	1,855,113,552.16	914,340,633.86	102.89%	Mainly due to the year-on-year increase in sales revenue for the current period and the fourth quarter of last year and the increase in cash collection.
2	Cash paid for goods and services	1,003,677,026.11	506,453,503.55	98.18%	Mainly due to the increase in purchase of corresponding raw materials as a result of the increase in orders.
3	Cash paid to and for employees	499,047,853.25	291,458,211.26	71.22%	Mainly due to the year-on-year increase in the number of employees and the payment of year-end bonus for 2021.
4	Taxes paid	95,750,534.24	46,203,019.03	107.24%	Mainly due to the year-on-year increase in taxes resulting from the significant increase in operating income.
5	Cash paid relating to other operating activities	122,781,583.52	67,916,564.63	80.78%	Mainly due to the payment of intermediary fees related to the listing and acquisition of H Shares and the payment of equipment rental deposits during the period.
6	Cash received from disposal of investments	607,807,000.00	–	100.00%	Mainly due to the maturity of wealth management products during the period.
7	Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	613,515,781.54	224,398,407.60	173.40%	Mainly due to the increase in orders on hand, expansion of production capacity and increase in investment in plant and equipment.
8	Cash paid for investments	1,099,322,000.00	15,000,000.00	7228.81%	Mainly due to the purchase of wealth management products during the period.
9	Net cash paid for acquisition of subsidiaries and other business units	30,090,000.00	–	100.00%	Mainly due to the payment for the acquisition of the equity interest in Beijing Improve Quality Technology Co., Ltd. during the period.
10	Cash received from capital contributions	387,731,358.82	26,378,880.00	1369.86%	Mainly due to the receipt of over-allotment of H shares during the period.
11	Impact of foreign exchange rate changes on cash and cash equivalents	-48,375,746.77	-3,147,007.99	1437.20%	Mainly due to the impact of exchange rate fluctuations during the period.
12	Cash and cash equivalents at the end of the period	5,642,739,406.29	1,990,297,803.19	183.51%	Mainly due to the receipt of over-allotment of H shares and the increase in sales proceeds during the period.

II. INFORMATION OF SHAREHOLDERS

(I) Total Number of Ordinary Shareholders and Number of Preferred Shareholders with Restored Voting Rights and Shareholdings of the Top Ten Shareholders

Unit: Share

Total number of ordinary shareholders at the end of the Reporting Period	26,675	Total number of preferred shareholders with restored voting rights at the end of the Reporting Period (if any)	0

Shareholdings of the top ten shareholders

Name of Shareholder	Nature of Shareholder	Shareholding ratio	Number of shares held	Number of restricted shares held	Pledged, tagged or frozen	
					Share status	Number
ASYMCHEM LABORATORIES, INCORPORATED	Foreign legal person	33.48%	88,510,520			
HKSCC NOMINEES LIMITED Note[1]	Foreign legal person	7.45%	19,680,900			
Industrial and Commercial Bank of China Limited – Central Europe Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司－中歐醫療健康混合型證券投資基金)	Domestic non-state-owned legal person	4.53%	11,987,613			
Hong Kong Securities Clearing Co., Ltd. (香港中央結算有限公司)	Foreign legal person	4.40%	11,643,631			
HAO HONG	Foreign natural person	3.86%	10,191,928	7,643,946		
Tianjin Guorong Business Information Co., Ltd. (天津國榮商務信息諮詢有限公司)	Domestic non-state-owned legal person	1.79%	4,743,360			
China Construction Bank Corporation – ICBC Credit Suisse Front Medical Securities Investment Fund	Domestic non-state-owned legal person	1.74%	4,603,000			
Bank of China Limited – Guangfa Healthcare Securities Investment Fund	Domestic non-state-owned legal person	1.27%	3,349,025			
Industrial and Commercial Bank of China Limited – Central Europe Healthcare Innovation Equity Securities Investment Fund (中國工商銀行股份有限公司－中歐醫療創新股票型證券投資基金)	Domestic natural person	1.08%	2,847,299			
Bank of China Limited – CMS International Biomedical Index Grading Securities Investment Fund (中國銀行股份有限公司－招商國證生物醫藥指數分級證券投資基金)	Domestic non-state-owned legal person	0.94%	2,472,607			

Shareholding of top ten shareholders without selling restrictions

Name of Shareholder	Number of shares held without selling restrictions	Types of shares	
		Types of shares	Number
ASYMCHEM LABORATORIES, INCORPORATED	88,510,520	RMB-dominated ordinary shares	88,510,520
HKSCC NOMINEES LIMITED Note[1]	19,680,900	Overseas listed foreign shares	19,680,900
Industrial and Commercial Bank of China Limited – Central Europe Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司－中歐醫療健康混合型證券投資基金)	11,987,613	RMB-dominated ordinary shares	11,987,613
Hong Kong Securities Clearing Co., Ltd. (香港中央結算有限公司)	11,643,631	RMB-dominated ordinary shares	11,643,631
#Tianjin Guorong Business Information Co., Ltd. (天津國榮商務信息諮詢有限公司)	4,743,360	RMB-dominated ordinary shares	4,743,360
China Construction Bank Corporation – ICBC Credit Suisse Front Medical Securities Investment Fund	4,603,000	RMB-dominated ordinary shares	4,603,000
Bank of China Limited – Guangfa Healthcare Securities Investment Fund	3,349,025	RMB-dominated ordinary shares	3,349,025
Industrial and Commercial Bank of China Limited – Central Europe Healthcare Innovation Equity Securities Investment Fund (中國工商銀行股份有限公司－中歐醫療創新股票型證券投資基金)	2,847,299	RMB-dominated ordinary shares	2,847,299
HAO HONG	2,547,982	RMB-dominated ordinary shares	2,547,982
Bank of China Limited – CMS International Biomedical Index Grading Securities Investment Fund (中國銀行股份有限公司－招商國證生物醫藥指數分級證券投資基金)	2,472,607	RMB-dominated ordinary shares	2,472,607

Illustrations on the connected relationship or acting in concert for the shareholders above

Mr. HAO HONG is the controlling shareholder and de facto controller of ALAB and is related to ALAB. Save for the above connected relationship, the Company is not aware of other shareholders who were connected or acted in concert with each other.

Note[1]: HKSCC NOMINEES LIMITED, being HKSCC Nominees Limited, holds shares on behalf of various customers.

Margin trading and short selling by top ten shareholders (if any)	Tianjin Guorong Business Information Co., Ltd. held 1,443,360 shares through ordinary securities accounts and 3,300,000 shares through credit securities accounts, totaling 4,743,360 shares.

(II) TOTAL NUMBER OF PREFERRED SHAREHOLDERS AND SHAREHOLDINGS OF THE TOP TEN PREFERRED SHAREHOLDINGS OF THE COMPANY

□ Applicable √ Not Applicable

III. OTHER SIGNIFICANT EVENTS

√ Applicable □ Not Applicable

18,415,400 overseas listed foreign shares (H Shares) issued by the Company were listed and traded on the Main Board of The Stock Exchange of Hong Kong Limited on December 10, 2021. According to the capital market conditions, the Company partially exercised the over-allotment option on January 2, 2022, involving a total of 1,265,500 H Shares. The over-allotment shares were listed on the Main Board of the Hong Kong Stock Exchange on January 5, 2022. Upon completion of the over-allotment, the A + H share capital of the Company will be 264,342,018 shares in total. For details, please refer to the relevant announcement (announcement no.: 2022-001) of the Company published on CNINFO on January 4, 2022.

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Financial Statement

1. Consolidated Balance Sheet

Prepared by: Asymchem Laboratories (Tianjin) Co., Ltd.
March 31, 2022

Unit: RMB

Item	Ending balance	Opening balance
Current Assets:		
Monetary funds	**5,642,739,406.29**	6,234,457,167.58
Clearing settlement funds		
Placements to banks and other financial institutions		
Financial assets held for trading	**887,856,000.00**	401,198,333.33
Derivative financial assets		
Bills receivable		
Accounts receivable	**2,051,597,484.61**	1,816,200,714.43
Financing receivables		
Prepayments	**435,948,192.20**	221,947,942.22
Premium receivables		
Reinsurance receivables		
Reinsurance contract reserves receivable		
Other receivables	**30,895,268.45**	23,116,427.35
Of which: Interest receivable		
Dividend receivable		
Financial assets held under resale agreements		
Inventories	**1,707,564,369.77**	1,396,115,127.88
Contract assets	**1,384,478.30**	742,372.74
Assets held for sale		
Non-current assets due within one year		
Other current assets	**302,446,881.76**	216,618,777.74
Total current assets	**11,060,432,081.38**	10,310,396,863.27

Item	Ending balance	Opening balance
Non-current assets:		
Loans and advances to customers		
Debt investments		
Other debt investments		
Long-term receivables		
Long-term equity investments	**296,514,893.14**	291,848,293.05
Other equity instrument investments		
Other non-current financial assets	**105,987,267.79**	103,766,285.39
Investment property		
Fixed assets	**2,613,729,469.76**	2,243,835,516.94
Construction in progress	**1,092,914,694.49**	1,047,257,690.87
Bearer biological assets		
Oil and gas assets		
Right-of-use assets	**53,553,840.65**	51,459,554.01
Intangible assets	**404,526,063.56**	374,149,170.78
Development expenditure		
Goodwill	**146,183,447.05**	146,183,447.05
Long-term prepaid expenses	**45,569,612.15**	45,760,526.90
Deferred income tax assets	**235,222,722.01**	186,930,443.93
Other non-current assets	**335,029,005.92**	354,709,478.15
Total non-current assets	**5,329,231,016.52**	4,845,900,407.07
Total assets	**16,389,663,097.90**	15,156,297,270.34

Item	Ending balance	Opening balance
Current liabilities:		
Short-term liabilities	**374,570,000.00**	375,391,841.31
Borrowings from central bank		
Due to banks and other financial institutions		
Financial liabilities held for trading		
Derivative financial liabilities		
Bills payable		
Accounts payable	**858,848,577.04**	551,866,159.80
Receipts in advance		
Contract liabilities	**144,736,116.12**	131,046,123.93
Financial assets sold under repurchase agreements		
Deposits from customers and other banks		
Accounts payable to brokerage clients		
Funds payable to securities issuers		
Staff remuneration payable	**126,950,201.74**	188,003,012.68
Taxes payable	**95,939,127.83**	88,677,283.16
Other payables	**869,963,763.62**	851,204,474.73
Of which: Interest payable		
Dividends payable		480,000.00
Fees and commissions payable		
Reinsurance accounts payable		
Liabilities held for sale		
Non-current liabilities due within one year	**13,049,619.54**	13,216,748.24
Other current liabilities	**7,357,083.06**	5,401,028.91
Total current liabilities	**2,491,414,488.95**	2,204,806,672.76

Item	Ending balance	Opening balance
Non-current liabilities:		
Insurance contract liabilities		
Long-term borrowings		
Bonds payable		
Of which: Preferred shares		
Perpetual debts		
Lease liabilities	**50,816,193.82**	45,877,025.18
Long-term payables		
Long-term staff remuneration payable		
Provision		
Deferred income	**175,665,164.35**	179,048,607.47
Deferred income tax liabilities	**157,589,389.65**	116,553,640.51
Other non-current liabilities		
Total non-current liabilities	**384,070,747.82**	341,479,273.16
Total liabilities	**2,875,485,236.77**	2,546,285,945.92
Owners' equity:		
Share capital	**264,281,818.00**	263,043,518.00
Other equity instruments		
Of which: Preferred shares		
Perpetual debts		
Capital reserve	**9,965,703,327.01**	9,564,303,921.76
Less: Treasury shares	**478,526,517.00**	481,820,001.00
Other comprehensive income	**-10,310,637.84**	-9,132,780.47
Special reserve		
Surplus reserve	**103,351,682.60**	103,351,682.60
General reserve		
Retained earnings	**3,669,678,188.36**	3,170,264,983.53
Total equity attributable to owners of the parent company	**13,514,177,861.13**	12,610,011,324.42
Minority interests		
Total owners' equity	**13,514,177,861.13**	12,610,011,324.42
Total liabilities and owners' equity	**16,389,663,097.90**	15,156,297,270.34

Legal representative: HAO HONG	Accounting chief: Zhang Da	Person-in-charge of the accounting department: Huang Mo

2. *Consolidated Statement of Profit*

Unit: RMB

Item	Amount for current period	Amount for previous period
I. Total operating revenue	**2,061,708,856.14**	777,189,276.45
Of which: Operating revenue	**2,061,708,856.14**	777,189,276.45
Interest income		
Premiums earned		
Handling fee and commission income		
II. Total operating costs	**1,501,478,969.64**	645,453,625.78
Of which: Operating cost	**1,128,892,034.57**	444,047,380.18
Interest expenses		
Handling fee and commission expenses		
Surrenders value		
Net expenditure for insurance claims settlement		
Net drawing on provision for insurance contracts		
Expenditures for policy dividend		
Reinsurance expenditures		
Tax and surcharges	**9,815,688.11**	7,375,051.12
Selling expenses	**20,540,724.40**	19,141,479.12
Management expenses	**162,978,091.37**	98,610,120.31
R&D expenses	**130,883,695.56**	83,440,733.89
Finance cost	**48,368,735.63**	-7,161,138.84
Of which: Interest fee	**3,712,440.70**	20,555.56
Interest income	**1,835,958.92**	5,259,764.50
Add: Other income	**8,038,406.63**	29,147,775.98
Gain from investment (loss is represented by "–")	**11,660,530.17**	-87,873.58
Of which: Gains from investment in associates and joint ventures		
Derecognition gains from financial assets measured at amortised cost		
Gains from exchange (loss is represented by "–")		
Gains on net exposure hedges (loss is represented by "–")		
Gains from change in fair value (loss is represented by "–")	**-1,376,129.87**	

Item	**Amount for current period**	Amount for previous period
Impairment loss of credit (loss is represented by "–")	**-8,455,030.68**	4,357,318.30
Impairment loss of assets (loss is represented by "–")		
Gain from assets disposal (loss is represented by "–")		
III. Operational profit (loss is represented by "–")	**570,097,662.75**	165,152,871.37
Add: Non-operating income	**9,320.64**	150,569.72
Less: Non-operating expense	**3,018,417.04**	12,762.81
IV. Total profit (total loss is represented by "–")	**567,088,566.35**	165,290,678.28
Less: Income tax expense	**67,690,481.54**	10,961,374.16
V. Net profit (net loss is represented by "–")	**499,398,084.81**	154,329,304.12
(I) Classified by continuity of operations		
1. Net profit from continuing operations (net loss is represented by "–")	**499,398,084.81**	154,329,304.12
2. Net profit from discontinued operations (net loss is represented by "–")		
(II) Classified by ownership of equity		
1. Net profit attributable to the shareholders of the parent company	**499,398,084.81**	154,330,479.55
2. Minority interests		-1,175.43
VI. Other comprehensive income, net of tax	**-6,310,310.96**	2,378,209.88
Other comprehensive income attributable to the owners of the parent company, net of tax	**-6,310,310.96**	2,378,209.88
(I) Other comprehensive income not to be reclassified to profit or loss		
1. Re-measurement of changes under defined benefit plan		
2. Other comprehensive income which cannot be reclassified to profit or loss under equity method		
3. Changes in fair value of other investments in equity instruments		
4. Change in fair value of the corporate's own credit risk		
5. Others		

Item	**Amount for current period**	Amount for previous period
(II) Other comprehensive income to be reclassified to profit or loss	**-6,310,310.96**	2,378,209.88
1. Other comprehensive income which can be reclassified to profit or loss under equity method		
2. Changes in fair value of other debt investments		
3. Amount included in other comprehensive income on reclassification of financial assets		
4. Provision for credit impairment of other debt investments		
5. Cash flows hedging reserve		
6. Differences on translation of foreign currency statements	**-6,310,310.96**	2,378,209.88
7. Others		
Other comprehensive income attributable to minority shareholders, net of tax		
VII. Total comprehensive income	**493,087,773.85**	156,707,514.00
Total comprehensive income attributable to the owners of the parent company	**493,087,773.85**	156,708,689.43
Total comprehensive income attributable to minority shareholders		-1,175.43
VIII. Earnings per share:		
(I) Basic earnings per share	**1.91**	0.64
(II) Diluted earnings per share	**1.90**	0.64

For the business consolidation under common control during the period, the net profit realised by the merged party before the combination was RMB0.00, and the net profit realised by the merged party in the previous period was RMB0.00.

Legal representative:	Accounting chief:	Person-in-charge of the accounting department:
HAO HONG	Zhang Da	Huang Mo

3. Consolidated Statement of Cash Flows

Unit: RMB

Item	**Amount for current period**	Amount for previous period
I. Cash flow from operating activities:		
Received from the sales of goods and the rendering of services	**1,855,113,552.16**	914,340,633.86
Net increase in deposits from customers and inter-bank deposits		
Net increase in borrowings from central bank		
Net increase in borrowings from other financial institutions		
Cash received from premiums under original insurance contracts		
Net cash received from reinsurance business		
Net increase in deposits from policyholder and investment funds		
Cash received from interest, handling fee and commission		
Net increase in capital borrowed		
Net increase in capital from repurchase business		
Net cash received from acting sale of securities		
Refund of taxes and levies	**63,366,768.52**	64,768,353.30
Cash received relating to other operating activities	**7,383,738.27**	33,581,391.91
Sub-total of cash inflows from operating activities	**1,925,864,058.95**	1,012,690,379.07
Cash paid to the purchase of goods and the acceptance of services	**1,003,677,026.11**	506,453,503.55
Net increase in loans and advances to customers		
Net increase in deposits with central bank and inter-bank deposits		
Cash paid for compensation payments under original insurance contracts		
Net increase in loans to banks and other financial institutions		
Cash paid for interest, handling fee and commission		
Cash paid for policyholder dividend		
Cash paid to and for employees	**499,047,853.25**	291,458,211.26
Payments of all types of taxes	**95,750,534.24**	46,203,019.03
Cash payments relating to other operating activities	**122,781,583.52**	67,916,564.63
Sub-total of cash outflows from operating activities	**1,721,256,997.12**	912,031,298.47
Net cash flow from operating activities	**204,607,061.83**	100,659,080.60

Item	Amount for current period	Amount for previous period
II. Cash flow from investing activities:		
Cash received from investment recovery	**607,807,000.00**	
Cash received from returns on investments	**3,330,118.87**	
Net cash received from disposals of fixed assets, intangible assets and other long-term assets		
Net cash received from disposals of subsidiaries and other operating units		
Cash received relating to other investing activities		
Sub-total of cash inflows from investing activities	**611,137,118.87**	
Cash paid to acquire fixed assets, intangible assets and other long-term assets	**613,515,781.54**	224,398,407.60
Cash paid for investments	**1,099,322,000.00**	15,000,000.00
Net increase of mortgaged loans		
Net cash paid for acquisition of subsidiaries and other operating units	**30,090,000.00**	
Cash payments relating to other investing activities		
Sub-total of cash outflows from investing activities	**1,742,927,781.54**	239,398,407.60
Net cash flow from investing activities	**-1,131,790,662.67**	-239,398,407.60

Item	Amount for current period	Amount for previous period
III. Cash flow from financing activities:		
Cash received from capital contribution	**387,731,358.82**	26,378,880.00
Of which: Cash received by subsidiaries from investments of minority shareholders		
Cash received from borrowings		
Cash received relating to other financing activities		
Sub-total of cash inflows from financing activities	**387,731,358.82**	26,378,880.00
Cash payments for debts settlement		10,000,000.00
Cash payments for distribution of dividends, profits, or interest expenses	**3,889,772.50**	54,472.22
Of which: Dividends and profits paid by subsidiaries to minority shareholders	**480,000.00**	
Cash payments relating to other financing activities		5,699,120.00
Sub-total of cash outflows from financing activities	**3,889,772.50**	15,753,592.22
Net cash flow from financing activities	**383,841,586.32**	10,625,287.78
IV. Effect of foreign exchange rate changes on cash and cash equivalents	**-48,375,746.77**	-3,147,007.99
V. Net increase in cash and cash equivalents	**-591,717,761.29**	-131,261,047.21
Add: Balance of cash and cash equivalents at the beginning of the period	**6,234,457,167.58**	2,121,558,850.40
VI. Balance of cash and cash equivalents at the end of the period	**5,642,739,406.29**	1,990,297,803.19

(II) Auditors' Report

Whether the first quarterly report is audited or not

□ Yes √ No

The first quarterly report of the Company is unaudited.